# Single-cell Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/single-cell-biotech

- Industry: Biotechnology
- Headquarters: Qingdao, China
- Website: www.singlecellbiotech.com
- Total disclosed funding: $28M
- Latest round: Series A (Jan 19, 2026)
- Investors on record: 5

## About

Established in 2014 and based in Qingdao, China, Qingdao Xingsai Biotechnology Co., Ltd., trading as Single-cell Biotech, operates as a biotechnology company that focuses on single-cell analyzers and supporting reagent consumables R&D. Xu Jian, co-founder of the company, is currently the director of the Bioenergy Research Office and the Single Cell Center of the Qingdao Institute of Energy, Chinese Academy of Sciences. In January 2026, Single-cell Biotech raised approximately CNY 100 million in series A++ led by new investor CASVC Investment Management, with participation from new investors Zheshang Capital Management and Shandong Finance Investment Group.

The company provides metabolic phenome based single-cell imaging, sorting, sequencing, and culture solutions for many fields, such as precision medicine, human and environmental micro-ecology, bioresource mining. The business of the company includes the development and commercialization of novel single-cell medical and scientific instruments. The company's products include instruments, kits & chips, and software. Instruments include CAST-R, FlowRACS, EasySort Lego and RACS-Seq. The software includes RamEX, RamDB, and RamLIS. Kits & chips include sampling for cell analysis, SCRS acquisition and Raman-activated cell sorting.

The company generates revenue by selling single-cell analytical instruments and supporting reagents and consumables include high-throughput flow Raman sorter FlowRACS, clinical single-cell Raman drug sensitivity fast test CAST-R, single-cell Raman light tweezer's sorter RACS-Seq.

The series A++ round of financing will focus on three strategic directions: deep integration of technology, building an intelligent ecosystem, and expanding into global markets.

## Funding rounds

- Series A, Jan 19, 2026, $14M — Zheshang Capital Management, Shandong Finance Investment Group, CASVC Investment Management
- Series A, Dec 12, 2023, $14M — Hengxu Capital, Peiyang Begonia

## Investors

- Hengxu Capital (https://capitalatlas.ai/funds/hengxu-capital) — Series A
- Peiyang Begonia — Series A
- Zheshang Capital Management (https://capitalatlas.ai/funds/zheshang-capital-management) — Series A
- Shandong Finance Investment Group (https://capitalatlas.ai/funds/shandong-finance-investment-group) — Series A
- CASVC Investment Management (https://capitalatlas.ai/funds/casvc-investment-management) — Series A